# Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

> **NCT02839694** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Neoplasm Metastasis
- Sarcoma
- Neoplasms, Germ Cell and Embryonal
- Melanoma

## Interventions

- **DRUG:** decitabine (DAC)
- **DRUG:** Tetrahydrouridine (THU)
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT02839694
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07-07
- **Primary completion:** 2017-04-26
- **Final completion:** 2017-04-26
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839694, "Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02839694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*